Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vivostat pushes expansion with €3m

This article was originally published in Clinica

Executive Summary

Vivostat's existing shareholders have pumped a further €3m ($3.8m) into the Danish wound healing technologies developer, enabling the firm to achieve profitability and advance its US strategy. The Medicon Valley-based company's products, an autologous fibrin sealant for use in surgery and an autologous gel with a high concentration of growth factors to treat non-healing wounds, are already marketed in most of Europe. Part of the new financing will help Vivostat further grow its European sales and boost its bottom line. The remainder of the funds will be used for preparing the company's investigational device exemption (IDE) application for its wound healing gel in the US, the first step towards breaking into the US market. Vivostat expects to submit the application to the FDA within the next three months. CEO Tom Bjerg Lauritzen told Clinica that the company will be looking for a partner or investor to finance the trials in the US and commercialise the product.

You may also be interested in...

Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?

Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.

Roche Dx' EMEA Head To Take Charge After Diggelmann Departs

Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.

Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio

Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts